
    
      OUTLINE:

      Patients receive either regimen A or regimen B.

      REGIMEN A: Patients (18 through 45 years old) receive fludarabine intravenously (IV) over 30
      minutes on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo total
      body irradiation (TBI) twice daily (BID) on days -4 to -1. Patients receive unmanipulated
      cord blood unit IV followed by NLA101 IV within the next 24 hours on day 0.

      REGIMEN B: Patients (18 through 65 years old) receive fludarabine IV over 30-60 minutes on
      days -6 to -3 and IV over 30 minutes on day -2, cyclophosphamide IV on day -6, and thiotepa
      IV over 2-4 hours on days -5 and -4. Patients receive unmanipulated cord blood unit IV
      followed by NLA101 IV within the next 24 hours on day 0.

      After completion of study treatment, patients are followed up at 180 days, 1 year, and 2
      years.
    
  